EliA CTD Screen, the most clinically relevant and reliable ... · PDF file EliA SmDp test EliA...

Click here to load reader

  • date post

    12-Aug-2020
  • Category

    Documents

  • view

    6
  • download

    0

Embed Size (px)

Transcript of EliA CTD Screen, the most clinically relevant and reliable ... · PDF file EliA SmDp test EliA...

  • Making a measurable difference EliA CTD Screen, the most clinically relevant and reliable CTD Screen, helps simplify patient diagnosis

  • Streamlining connective tissue disease (CTD) diagnostics The EliA™ CTD Screen workflow can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1*,2**

    EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8

    90.4-93.4% negative1*, 2** Common panel

    Refer to specialist

    care

    Complex case panels

    EliA CTD Screen

    EliA dsDNA test

    EliA Mi-2 test

    EliA Fibrillarin test

    EliA PCNA test

    EliA RNA Pol III test

    EliA Rib-P test

    EliA PM-Scl test

    EliA Ro test

    EliA La test

    EliA U1RNP test

    EliA Scl-70s test

    EliA SmDp test

    EliA Jo-1 test

    EliA CENP test

    Primary Differentiators

    Secondary Differentiators

    *Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen. **Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.

    if from Primary Care

    The superior specificity of EliA CTD Screen, based on 2,000 patients being tested, and a disease prevalence of 1%, leads to 158 fewer false positives per year.8

    100

    50

    0 EliA CTD Screen ANA IIF

    92% 84%

    Sensitivity Specificity

    90% 76%

    Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.

    Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.

    *Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen. **Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.

  • Simplifying laboratory life Optimised workflow – supporting your lean approach

    Your partner – offering the complete support package to make the transition to EliA CTD Screen smooth

    One operator, one footprint, one maintenance, one service programme, one solution for allergy and autoimmunity

    No manual preparation necessary and with the flexibility to load and unload carriers

    The same wash buffer, stop solution, development solution – improving cost and time efficiencies

    One calibration curve per method stored for one month (IgG, IgM, IgA, IgE, calprotectin, anti-TSH-R) – maximising workflow efficiencies

    Ability to run requests as and when they arriveHigh on-board carrier/test capacity

    Ready to use carriers/reagents

    System reagents are suitable for both EliA and ImmunoCAPTM tests

    Efficient, flexible, calibration system

    One system, one sample, multiple tests

    Educational meetings for

    your laboratory

    Scientific support with results

    interpretation

    Letter for HCP to understand why/what has

    changed

    Support with educational

    meetings for your clinical customers

  • Making a measurable difference Why choose Thermo Fisher Scientific as your partner in connective tissue disease diagnostics?

    Streamlined diagnoses

    EliA CTD Screen; a single test that includes 17 autoantibodies; can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1,2

    Accurate results

    EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8

    Efficient workflow

    EliA CTD Screen is run on a fully automated, workflow optimised, Phadia™ Instrument, helping increase turnaround time in your laboratory

    REFERENCES 1. Willems P, et al. Clin Chem Lab Med 2018;56;909-18. 2. Robier C, et al. Clin Chem Lab Med 2016;54(8):1365-70. 3. Korsholm T, et al. Scand J Rheumatol 2014;43:89. 4. Pereira LM, et al. EliA Journal 2010 (Special Edition 1):6-7. 5. Alpini C, et al. EliA Journal 2010 (Special Edition 1):3.18. 6. Otten HG, et al. Clin Exp Rheumatol 2017. 7. Jeong S, et al. PLoS ONE 2017;12(3). 8. van der Pol P, et al. Clinica Chimica Acta 2018;476:154-159.

    Find out more at allergyai.com/uk/lab © 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 2019-26.AI.EU1.EN.v1.19